NCT06007872 Intracardiac Echocardiography Guided Watchman Device Implant
| NCT ID | NCT06007872 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Cleveland Clinic |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-12-02 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-12-02 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to look at the success of Intracardiac Echocardiography (ICE) in the Watchman procedure. Currently the process is to use a Transesophageal Echocardiography (TEE) to place the Watchman in patients. This study is aiming to show how the ICE is just as effective in placing the device correctly and effectively.
Eligibility Criteria
Inclusion Criteria: * All patients who meet guideline established criteria for commercially available Watchman device implant and not enrolled in an active clinical trial Exclusion Criteria: * Patients in whom a procedural TEE cannot be performed and an ICE only implant is needed. * Patients receiving a concomitant ablation procedure * Patients with prior incomplete surgical or percutaneous left atrial appendage ligation/exclusion procedures * Patients in whom the delivery of trans-septal equipment is anticipated to be difficult (e.g. patent foramen ovale (PFO) or atrial septal defect (ASD) closure devices in place).
Contact & Investigator
Oussama Wazni, MD
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT06007872 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06007872 currently recruiting?
Yes, NCT06007872 is actively recruiting participants. Contact the research team at waznio@ccf.org for enrollment information.
Where is the NCT06007872 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT06007872 clinical trial?
NCT06007872 is sponsored by The Cleveland Clinic. The principal investigator is Oussama Wazni, MD at The Cleveland Clinic. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.